{"id":10955,"date":"2023-04-27T15:36:22","date_gmt":"2023-04-27T20:36:22","guid":{"rendered":"https:\/\/www.voicesforvaccines.org\/?post_type=jtf_topics&p=10955"},"modified":"2024-08-12T15:41:10","modified_gmt":"2024-08-12T20:41:10","slug":"rsv-in-adults","status":"publish","type":"jtf_topics","link":"https:\/\/www.voicesforvaccines.org\/es\/jtf_topics\/rsv-in-adults\/","title":{"rendered":"RSV in adults"},"content":{"rendered":"
[vc_row source=”” text=”Clinical Trials” font_container=”tag:h2|text_align:left” use_theme_fonts=”yes” google_fonts=”font_family:Abril%20Fatface%3Aregular|font_style:400%20regular%3A400%3Anormal” link=”” css=”.vc_custom_1708910874436{border-top-width: 1px !important;border-right-width: 1px !important;border-bottom-width: 1px !important;border-left-width: 1px !important;}”][vc_column][vc_row_inner][vc_column_inner][vc_custom_heading text=”The Claim:” font_container=”tag:h3|text_align:left” use_theme_fonts=”yes”][vc_column_text css=””]\n
\n
\n
\n
\n
\n
\n

A\u00a0cardiologist-turned-wellness influencer<\/a>\u00a0claims that the RSV vaccine\u2019s risks outweigh the benefits in adults.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_custom_heading text=”The Facts:” font_container=”tag:h3|text_align:left” use_theme_fonts=”yes”][vc_column_text css=””]The CDC\u00a0estimates<\/a>\u00a0that\u00a0between 60,000-160,000 older adults in the United States are hospitalized every year due to RSV infection, and 6,000-10,000 of them die. Additionally, these adults can act as vectors spreading RSV to others, including to infants, for whom RSV can be\u00a0deadly<\/a>.<\/p>\n

The adult RSV vaccines under development have shown promising results in\u00a0clinical trials<\/a>, showing an efficacy of about 85%\u00a0without safety concerns. Rates of severe adverse events were similar in both the vaccine group and the placebo group, implying that the vaccine\u2019s benefit outweighs the risks.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"

The adult RSV vaccines under development have shown promising results in\u00a0clinical trials, showing an efficacy of about 85%\u00a0without safety concerns.<\/p>\n","protected":false},"parent":0,"template":"","jtf_topic_subjects":[217,218],"class_list":["post-10955","jtf_topics","type-jtf_topics","status-publish","hentry","jtf_topic_subjects-rsv","jtf_topic_subjects-vaccine-safety","entry","no-media"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/jtf_topics\/10955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/jtf_topics"}],"about":[{"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/types\/jtf_topics"}],"version-history":[{"count":1,"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/jtf_topics\/10955\/revisions"}],"predecessor-version":[{"id":10958,"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/jtf_topics\/10955\/revisions\/10958"}],"wp:attachment":[{"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/media?parent=10955"}],"wp:term":[{"taxonomy":"jtf_topic_subjects","embeddable":true,"href":"https:\/\/www.voicesforvaccines.org\/es\/wp-json\/wp\/v2\/jtf_topic_subjects?post=10955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}